A Randomized Phase IIa Study of Vorinostat in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome.
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2013
At a glance
- Drugs Vorinostat (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 26 Jan 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 28 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.